Almirall´s ImmunoSkin gathers leading experts to advance the science and treatment of inflammatory skin conditions

BARCELONA, Spain. 11^th November 2025 – Almirall, a global biopharmaceutical company dedicated to medical dermatology, hosted the 4^th edition of ImmunoSkin, its annual scientific meeting focused on chronic inflammatory skin conditions.  This year’s event was held from 8^th to 9^th November in Madrid and chaired by Dr. Christian Vestergaard, MD, PhD, DMSc, Professor and Dermatologist at the Department of Dermatology at Aarhus University Hospital, Denmark. Leading international experts discussed the latest scientific advancements, and innovative treatment approaches, as well as the broader impact of inflammatory skin conditions on patients.

Almirall´s ImmunoSkin is a key pillar of the company´s dedication to advancing the scientific understanding of skin and its conditions, facilitating scientific exchange and bringing together a community of experts with the goal of enhancing health outcomes for patients with immune-mediated skin diseases.

The discussions focused on four essential pillars which are essential drivers of treatment success in immune-modulated skin diseases: new concepts in the immunology of the skin, clinical perspectives, patient perspectives, and recent and future innovation in dermatology.

Workshops dedicated to clinical perspectives on immune-modulated skin diseases featured the treatment of some of the most prevalent and impactful inflammatory skin conditions, including Atopic dermatitis and Psoriasis. Latest data from advanced treatment options targeting IL-13 (for Atopic dermatitis) and IL-23 (for Psoriasis) were discussed and highlighted advances in understanding treatment success. Insights into recent and future innovation in dermatology included new data on immune-therapeutic treatment options, T-cell biology, and innovative approaches towards understanding and treating conditions like Hidradenitis suppurativa and Alopecia areata. The future outlook on the impact of advanced treatments included the potential to achieve a reset of the immune system that could lead to disease modification with a lasting impact on patients living with chronic skin conditions.

The discussion on further driving holistic approaches to patient care revolved around the importance of considering psychological well-being and quality of life as well as the impact on patients’ partners and families as key pillars of the patient‑centred approach called for in the WHO’s 2025 resolution on skin diseases as a global public health priority. Clinical and real-world-evidence data using the World Health Organization Well-Being Index (WHO-5) as a primary endpoint have established the significant psychological impact chronic skin conditions can have on patients, as well as the positive effect advanced treatments can deliver beyond resolution of the physical symptoms.

Dr. Christian Vestergaard, MD, PhD, DMSc, Professor and Dermatologist and chair of the conference, remarked, “ImmunoSkin is a unique opportunity to focus on advancing our understanding of inflammatory skin diseases and their treatments. The focus on collaboration and scientific exchange, paired with sharing foundational patient insights on inflammatory skin diseases and treatment outcomes is immensely powerful to further drive treatment success and patient outcomes for some of the most debilitating dermatological conditions.”

Volker Koscielny, M.D., Chief Medical Officer at Almirall, added, “Advancing science and treatment success for skin diseases is based on collaboration and expert exchange – this is what the multi-faceted and meaningful exchange at ImmunoSkin facilitates, bringing together clinicians and international thought leaders in Dermatology. We are proud to contribute in improving treatment outcomes for patients suffering from skin diseases – from increasing understanding at the molecular level all the way to psychological well-being.”

About ImmunoSkin

ImmunoSkin is Almirall’s annual scientific meeting dedicated to chronic inflammatory skin conditions. Now in its fourth edition, ImmunoSkin has become a leading international meeting for dermatologists, bringing together leading experts from around the world to foster collaboration, exchange breakthrough insights and advance the understanding of autoimmune skin diseases to enhance patient care. Together, the participants share high-level scientific content, focusing on advancements in research, and exploring innovative treatment options for inflammatory skin conditions. Building on its established success, Almirall continues to advance education and best practice sharing within the global dermatological community. 

About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

For more information, please visit https://www.almirall.com/

Corporate Communications:                              Investor Relations

corporate.communication@almirall.com             investors@almirall.com

Phone: +34 93 291 35 08                                    Phone: (+34) 93 291 30 87          

Legal notice:

This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are "forward-looking statements." These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.